BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20810784)

  • 1. Functional interactions as a survival strategy against abnormal aggregation.
    Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
    FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
    Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
    Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
    J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites.
    Nicastro G; Masino L; Esposito V; Menon RP; De Simone A; Fraternali F; Pastore A
    Biopolymers; 2009 Dec; 91(12):1203-14. PubMed ID: 19382171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
    Nicastro G; Todi SV; Karaca E; Bonvin AM; Paulson HL; Pastore A
    PLoS One; 2010 Aug; 5(8):e12430. PubMed ID: 20865150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of substrate recognition by the Josephin domain of ataxin-3, which has an endo-type deubiquitinase activity.
    Satoh T; Sumiyoshi A; Yagi-Utsumi M; Sakata E; Sasakawa H; Kurimoto E; Yamaguchi Y; Li W; Joazeiro CA; Hirokawa T; Kato K
    FEBS Lett; 2014 Nov; 588(23):4422-30. PubMed ID: 25448680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of a Josephin-ubiquitin complex: evolutionary restraints on ataxin-3 deubiquitinating activity.
    Weeks SD; Grasty KC; Hernandez-Cuebas L; Loll PJ
    J Biol Chem; 2011 Feb; 286(6):4555-65. PubMed ID: 21118805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3.
    Chow MK; Mackay JP; Whisstock JC; Scanlon MJ; Bottomley SP
    Biochem Biophys Res Commun; 2004 Sep; 322(2):387-94. PubMed ID: 15325242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
    Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
    J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3.
    Gales L; Cortes L; Almeida C; Melo CV; Costa MC; Maciel P; Clarke DT; Damas AM; Macedo-Ribeiro S
    J Mol Biol; 2005 Oct; 353(3):642-54. PubMed ID: 16194547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils.
    Masino L; Nicastro G; De Simone A; Calder L; Molloy J; Pastore A
    Biophys J; 2011 Apr; 100(8):2033-42. PubMed ID: 21504740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis.
    Ricchelli F; Fusi P; Tortora P; Valtorta M; Riva M; Tognon G; Chieregato K; Bolognin S; Zatta P
    Int J Biochem Cell Biol; 2007; 39(5):966-77. PubMed ID: 17300980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteotoxic stress increases nuclear localization of ataxin-3.
    Reina CP; Zhong X; Pittman RN
    Hum Mol Genet; 2010 Jan; 19(2):235-49. PubMed ID: 19843543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
    Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
    Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of amino acid homo-sequences in proteins: insights into the role of amino acid homo-polymers and of the protein context in aggregation.
    Menon RP; Pastore A
    Cell Mol Life Sci; 2006 Jul; 63(14):1677-85. PubMed ID: 16791428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes.
    Tzvetkov N; Breuer P
    Biol Chem; 2007 Sep; 388(9):973-8. PubMed ID: 17696782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain.
    Mao Y; Senic-Matuglia F; Di Fiore PP; Polo S; Hodsdon ME; De Camilli P
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12700-5. PubMed ID: 16118278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA; de Macedo-Ribeiro S; Carvalho AL
    Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways.
    Chai Y; Berke SS; Cohen RE; Paulson HL
    J Biol Chem; 2004 Jan; 279(5):3605-11. PubMed ID: 14602712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.